Veranova appoints Joe Torres-Ocasio as senior vice president and chief operating officer
Charlie Blackie-Kelly | October 2, 2025 | Appointment | | Veranova, antibody-drug conjugates, appointment
Appointment follows significant investment into US manufacturing footprint
Active pharmaceutical ingredient (API) manufacturer Veranova has appointed Joe Torres-Ocasio as senior vice president and chief operating officer.
Torres-Ocasio most recently served as vice president of global operations for the biologics division at Catalent, where he played a key role in transforming several major operations. He began his career at Amgen as a manufacturing leader and later held senior operational roles at Immucor and Therapeutic Proteins. He also served as regional vice president at Baxter Healthcare, overseeing the development of multiple sites.
“Joe’s deep operational expertise and proven leadership track record make him an exceptional addition to our leadership team” said Mike Riley, CEO of Veranova. “His ability to drive transformational change at scale across multiple technologies will be instrumental in driving operational excellence and delivering value to our customers and patients.”
In his new role, Torres-Ocasio will oversee Veranova’s operations across manufacturing sites in North America and Europe. He will also assume responsibility for the company’s engineering, environmental health and safety (EHS), supply chain, and operational excellence functions.
The appointment follows Veranova’s recent investment in strengthening its US manufacturing capabilities, including a $50m expansion of its Devens, Massachusetts facility. The upgrade is designed to boost domestic production of antibody-drug conjugates (ADCs), novel bioconjugates, and other APIs for US pharma and biotech companies.
Related Content
Lonza and Engitix partner to develop next-generation antibody-drug conjugates
Lonza and Engitix have entered into a licensing agreement to support the development of antibody-drug …
David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …
